Ultrahigh-field MRI: where it really makes a difference
Open Access
- 16 August 2023
- journal article
- review article
- Published by Springer Nature in Die Radiologie
- Vol. 64 (S1) , 1-8
Abstract
Background: Currently, two major magnetic resonance (MR) vendors provide commercial 7‑T scanners that are approved by the Food and Drug Administration (FDA) for clinical application. There is growing interest in ultrahigh-field MRI because of the improved clinical results in terms of morphological detail, as well as functional and metabolic imaging capabilities. Materials and methods: The 7‑T systems benefit from a higher signal-to-noise ratio, which scales supralinearly with field strength, a supralinear increase in the blood oxygenation level dependent (BOLD) contrast for functional MRI and susceptibility weighted imaging (SWI), and the chemical shift increases linearly with field strength with consequently higher spectral resolution. Results: In multiple sclerosis (MS), 7‑T imaging enables visualization of cortical lesions, the central vein sign, and paramagnetic rim lesions, which may be beneficial for the differential diagnosis between MS and other neuroinflammatory diseases in challenging and inconclusive clinical presentations and are seen as promising biomarkers for prognosis and treatment monitoring. The recent development of high-resolution proton MR spectroscopic imaging in clinically reasonable scan times has provided new insights into tumor metabolism and tumor grading as well as into early metabolic changes that may precede inflammatory processes in MS. This technique also improves the detection of epileptogenic foci in the brain. Multi-nuclear clinical applications, such as sodium imaging, have shown great potential for the evaluation of repair tissue quality after cartilage transplantation and in the monitoring of newly developed cartilage regenerative drugs for osteoarthritis. Conclusion: For special clinical applications, such as SWI in MS, MR spectroscopic imaging in tumors, MS and epilepsy, and sodium imaging in cartilage repair, 7T may become a new standard.Keywords
Funding Information
- Medical University of Vienna
This publication has 33 references indexed in Scilit:
- 7T MR spectroscopic imaging in the localization of surgical epilepsyEpilepsia, 2013
- Evaluation of native hyaline cartilage and repair tissue after two cartilage repair surgery techniques with 23Na MR imaging at 7 T: initial experienceOsteoarthritis and Cartilage, 2012
- Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosisMultiple Sclerosis Journal, 2012
- Sodium inversion recovery MRI of the knee joint in vivo at 7TJournal of Magnetic Resonance, 2010
- 23Na MR Imaging at 7 T after Knee Matrix–associated Autologous Chondrocyte Transplantation Preliminary ResultsRadiology, 2010
- Magnetic susceptibility mapping of brain tissue in vivo using MRI phase dataMagnetic Resonance in Medicine, 2009
- A Comparison of 3T and 7T in the Detection of Small Parenchymal Veins Within MS LesionsInvestigative Radiology, 2009
- Susceptibility weighted imaging at ultra high magnetic field strengths: Theoretical considerations and experimental resultsMagnetic Resonance in Medicine, 2008
- Gd‐DTPA2− as a measure of cartilage degradationMagnetic Resonance in Medicine, 1996
- The correlation of fixed negative charge with glycosaminoglycan content of human articular cartilageBiochimica et Biophysica Acta (BBA) - General Subjects, 1969